As of Oct 17
| +1.05 / +9.11%|
The 6 analysts offering 12-month price forecasts for Orchard Therapeutics PLC have a median target of 27.00, with a high estimate of 31.00 and a low estimate of 21.00. The median estimate represents a +114.63% increase from the last price of 12.58.
The current consensus among 6 polled investment analysts is to Buy stock in Orchard Therapeutics PLC. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.